Cell signaling pathways that regulate antigen presentation

Journal of Immunology

Volumn 197, Issue 8, 2016, Pages 2971-2979

  Brutkiewicz, Randy R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; APOPTOSIS; AUTOIMMUNITY; CELL DEATH; CELL SURFACE; CELLULAR STRESS RESPONSE; HUMAN; IMMUNE RESPONSE; INFECTION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; INTRACELLULAR SPACE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; ANIMAL; AUTOIMMUNE DISEASE; IMMUNOLOGY; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

SIGNAL PEPTIDE; VACCINE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, INNATE; INFECTION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VACCINES;

EID: 84991449435     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600460     Document Type: Review

References (129)

1. Blum, J. S., P. A. Wearsch, and P. Cresswell. 2013. Pathways of antigen processing. Annu. Rev. Immunol. 31: 443-473.
2. Springer, S. 2015. Transport and quality control of MHC class I molecules in the early secretory pathway. Curr. Opin. Immunol. 34: 83-90.
3. Mintern, J. D., C. Macri, and J. A. Villadangos. 2015. Modulation of antigen presentation by intracellular trafficking. Curr. Opin. Immunol. 34: 16-21.
4. Adiko, A. C., J. Babdor, E. Gutiérrez-Martńez, P. Guermonprez, and L. Saveanu. 2015. Intracellular transport routes for MHC I and their relevance for antigen cross-presentation. Front. Immunol. 6: 335.
5. McEwen-Smith, R. M., M. Salio, and V. Cerundolo. 2015. CD1d-dependent endogenous and exogenous lipid antigen presentation. Curr. Opin. Immunol. 34: 116-125.
6. Ackerman, A. L., and P. Cresswell. 2003. Regulation of MHC class I transport in human dendritic cells and the dendritic-like cell line KG-1. J. Immunol. 170: 4178-4188.
7. + dendritic cells by Japanese encephalitis virus in a TLR2/MyD88 signal pathway-dependent manner. Eur. J. Immunol. 42: 2655-2666.
8. + conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface. J. Immunol. 190: 948-960.
9. Heise, R., P. M. Amann, S. Ensslen, Y. Marquardt, K. Czaja, S. Joussen, D. Beer, R. Abele, G. Plewnia, R. Tampé, et al. 2016. Interferon alpha signalling and its relevance for the upregulatory effect of transporter proteins associated with antigen processing (TAP) in patients with malignant melanoma. PLoS One 11: e0146325.
10. MacAry, P. A., M. Lindsay, M. A. Scott, J. I. Craig, J. P. Luzio, and P. J. Lehner. 2001. Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells. Proc. Natl. Acad. Sci. USA 98: 3982-3987.
11. Nair-Gupta, P., A. Baccarini, N. Tung, F. Seyffer, O. Florey, Y. Huang, M. Banerjee, M. Overholtzer, P. A. Roche, R. Tampé, et al. 2014. TLR signals induce phagosomal MHC-I delivery from the endosomal recycling compartment to allow cross-presentation. Cell 158: 506-521.
12. Rodŕguez, T., R. Méndez, A. Del Campo, P. Jiménez, N. Aptsiauri, F. Garrido, and F. Ruiz-Cabello. 2007. Distinct mechanisms of loss of IFN-γamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 7: 34.
13. Shen, K. Y., Y. C. Song, I. H. Chen, C. H. Leng, H. W. Chen, H. J. Li, P. Chong, and S. J. Liu. 2014. Molecular mechanisms of TLR2-mediated antigen crosspresentation in dendritic cells. J. Immunol. 192: 4233-4241.
14. Svane, I. M., A. M. Engel, M. Nielsen, and O. Werdelin. 1997. Interferongamma-induced MHC class I expression and defects in Jak/Stat signalling in methylcholanthrene-induced sarcomas. Scand. J. Immunol. 46: 379-387.
15. Weck, M. M., F. Grunebach, D. Werth, C. Sinzger, A. Bringmann, and P. Brossart. 2007. TLR ligands differentially affect uptake and presentation of cellular antigens. Blood 109: 3890-3894.
16. Zhou, F. 2009. Molecular mechanisms of viral immune evasion proteins to inhibit MHC class I antigen processing and presentation. Int. Rev. Immunol. 28: 376-393.
17. Nair, P., D. Amsen, and J. M. Blander. 2011. Co-ordination of incoming and outgoing traffic in antigen-presenting cells by pattern recognition receptors and T cells. Traffic 12: 1669-1676.
18. Wagner, C. S., and P. Cresswell. 2012. TLR and nucleotide-binding oligomerization domain-like receptor signals differentially regulate exogenous antigen presentation. J. Immunol. 188: 686-693.
19. Abendroth, A., B. Slobedman, E. Lee, E. Mellins, M. Wallace, and A. M. Arvin. 2000. Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J. Virol. 74: 1900-1907.
20. Andreae, S., S. Buisson, and F. Triebel. 2003. MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). Blood 102: 2130-2137.
21. Bailey, J. C., A. K. Iyer, G. J. Renukaradhya, Y. Lin, H. Nguyen, and R. R. Brutkiewicz. 2014. Inhibition of CD1d-mediated antigen presentation by the transforming growth factor-b/Smad signalling pathway. Immunology 143: 679-691.
22. Blander, J. M., and R. Medzhitov. 2006. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440: 808-812.
23. Chen, Y. W., M. L. Lang, andW. F.Wade. 2004. Protein kinase C-alpha and-delta are required for FcalphaR (CD89) trafficking to MHC class II compartments and FcalphaR-mediated antigen presentation. Traffic 5: 577-594.
24. Delamarre, L., H. Holcombe, and I. Mellman. 2003. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J. Exp. Med. 198: 111-122.
25. Gehring, A. J., K. M. Dobos, J. T. Belisle, C. V. Harding, and W. H. Boom. 2004. Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macrophage class II MHC antigen processing. J. Immunol. 173: 2660-2668.
26. Letran, S. E., S. J. Lee, S. M. Atif, S. Uematsu, S. Akira, and S. J. McSorley. 2011. TLR5 functions as an endocytic receptor to enhance flagellin-specific adaptive immunity. Eur. J. Immunol. 41: 29-38.
27. Majewski, M., T. O. Bose, F. C. Sillé, A. M. Pollington, E. Fiebiger, and M. Boes. 2007. Protein kinase C delta stimulates antigen presentation by Class II MHC in murine dendritic cells. Int. Immunol. 19: 719-732.
28. Miller, D. M., B. M. Rahill, J. M. Boss, M. D. Lairmore, J. E. Durbin, J. W. Waldman, and D. D. Sedmak. 1998. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J. Exp. Med. 187: 675-683.
29. Olson, J. K., and S. D. Miller. 2004. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J. Immunol. 173: 3916-3924.
30. Simmons, D. P., P. A. Wearsch, D. H. Canaday, H. J. Meyerson, Y. C. Liu, Y. Wang, W. H. Boom, and C. V. Harding. 2012. Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J. Immunol. 188: 3116-3126.
31. Uetani, K., M. Hiroi, T. Meguro, H. Ogawa, T. Kamisako, Y. Ohmori, and S. C. Erzurum. 2008. Influenza A virus abrogates IFN-γamma response in respiratory epithelial cells by disruption of the Jak/Stat pathway. Eur. J. Immunol. 38: 1559-1573.
32. Kain, L., A. Costanzo, B. Webb, M. Holt, A. Bendelac, P. B. Savage, and L. Teyton. 2015. Endogenous ligands of natural killer T cells are alpha-linked glycosylceramides. Mol. Immunol. 68(2 Pt A): 94-97.
33. Van Rhijn, I., D. I. Godfrey, J. Rossjohn, and D. B. Moody. 2015. Lipid and small-molecule display by CD1 and MR1. Nat. Rev. Immunol. 15: 643-654.
34. Le Bourhis, L., Y. K. Mburu, and O. Lantz. 2013. MAIT cells, surveyors of a new class of antigen: development and functions. Curr. Opin. Immunol. 25: 174-180.
35. McWilliam, H. E., R. W. Birkinshaw, J. A. Villadangos, J. McCluskey, and J. Rossjohn. 2015. MR1 presentation of vitamin B-based metabolite ligands. Curr. Opin. Immunol. 34: 28-34.
36. Arthur, J. S., and S. C. Ley. 2013. Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol. 13: 679-692.
37. Rincón, M., R. A. Flavell, and R. A. Davis. 2000. The JNK and P38 MAP kinase signaling pathways in T cell-mediated immune responses. Free Radic. Biol. Med. 28: 1328-1337.
38. Lu, H. T., D. D. Yang, M. Wysk, E. Gatti, I. Mellman, R. J. Davis, and R. A. Flavell. 1999. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J. 18: 1845-1857.
39. Bunyard, P., M. Handley, G. Pollara, K. Rutault, I. Wood, M. Chaudry, C. Alderman, J. Foreman, D. R. Katz, and B. M. Chain. 2003. Ribotoxic stress activates p38 and JNK kinases and modulates the antigen-presenting activity of dendritic cells. Mol. Immunol. 39: 815-827.
40. Xie, J., J. Qian, J. Yang, S. Wang, M. E. Freeman, III, and Q. Yi. 2005. Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Exp. Hematol. 33: 564-572.
41. Khan, M. A., V. Sriram, G. J. Renukaradhya, W. Du, J. Gervay-Hague, and R. R. Brutkiewicz. 2008. Apoptosis-induced inhibition of CD1d-mediated antigen presentation: different roles for caspases and signal transduction pathways. Immunology 125: 80-90.
42. Renukaradhya, G. J., M. A. Khan, D. Shaji, and R. R. Brutkiewicz. 2008. Vesicular stomatitis virus matrix protein impairs CD1d-mediated antigen presentation through activation of the p38 MAPK pathway. J. Virol. 82: 12535-12542.
43. Renukaradhya, G. J., T. J. Webb, M. A. Khan, Y. L. Lin, W. Du, J. Gervay-Hague, and R. R. Brutkiewicz. 2005. Virus-induced inhibition of CD1d1-mediated antigen presentation: reciprocal regulation by p38 and ERK. J. Immunol. 175: 4301-4308.
44. Ardeshna, K. M., A. R. Pizzey, S. Devereux, and A. Khwaja. 2000. The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocytederived dendritic cells. Blood 96: 1039-1046.
45. Rescigno, M., M. Martino, C. L. Sutherland, M. R. Gold, and P. Ricciardi-Castagnoli. 1998. Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med. 188: 2175-2180.
46. Jörgl, A., B. Platzer, S. Taschner, L. X. Heinz, B. Höcher, P. M. Reisner, F. Göbel, and H. Strobl. 2007. Human Langerhans-cell activation triggered in vitro by conditionally expressed MKK6 is counterregulated by the downstream effector RelB. Blood 109: 185-193.
47. Bharadwaj, U., R. Zhang, H. Yang, M. Li, L. X. Doan, C. Chen, and Q. Yao. 2005. Effects of cyclophilin A on myeloblastic cell line KG-1 derived dendritic like cells (DLC) through p38 MAP kinase activation. J. Surg. Res. 127: 29-38.
48. Seshasayee, D., H. Wang, W. P. Lee, P. Gribling, J. Ross, N. Van Bruggen, R. Carano, and I. S. Grewal. 2004. A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J. Biol. Chem. 279: 30202-30209.
49. + T cell memory responses. J. Immunol. 172: 6047-6056.
50. + T cell epitope recognition paradigms. Science 340: 1237874.
51. Turnis, M. E., X. T. Song, A. Bear, A. E. Foster, S. Gottschalk, M. K. Brenner, S. Y. Chen, and C. M. Rooney. 2010. IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J. Immunol. 185: 4223-4232.
52. Park, S. Y., and Y. Kim. 2009. Surfactin inhibits immunostimulatory function of macrophages through blocking NK-kappaB, MAPK and Akt pathway. Int. Immunopharmacol. 9: 886-893.
53. Palová-Jeĺnková, L., D. Rozková, B. Pecharová, J. Bártová, A. Sedivá, H. Tlaskalová-Hogenová, R. Sṕsek, and L. Tucková. 2005. Gliadin fragments induce phenotypic and functional maturation of human dendritic cells. J. Immunol. 175: 7038-7045.
54. Wang, S., S. Hong, J. Yang, J. Qian, X. Zhang, E. Shpall, L. W. Kwak, and Q. Yi. 2006. Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 108: 4071-4077.
55. Gagliardi, M. C., R. Teloni, F. Giannoni, S. Mariotti, M. E. Remoli, V. Sargentini, M. Videtta, M. Pardini, G. De Libero, E. M. Coccia, and R. Nisini. 2009. Mycobacteria exploit p38 signaling to affect CD1 expression and lipid antigen presentation by human dendritic cells. Infect. Immun. 77: 4947-4952.
56. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278: 1626-1629.
57. Stuart, J. K., S. P. Bisch, M. Leon-Ponte, J. Hayatsu, D. M. Mazzuca, S. Maleki Vareki, and S. M. Haeryfar. 2010. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase. Int. Immunopharmacol. 10: 1068-1076.
58. +) T cell activation. J. Exp. Med. 195: 811-823.
59. +) T cell-mediated antiviral immunity. J. Exp. Med. 195: 801-810.
60. Valledor, A. F., M. Comalada, J. Xaus, and A. Celada. 2000. The differential timecourse of extracellular-regulated kinase activity correlates with the macrophage response toward proliferation or activation. J. Biol. Chem. 275: 7403-7409.
61. Monick, M. M., A. B. Carter, D. M. Flaherty, M. W. Peterson, and G. W. Hunninghake. 2000. Protein kinase C zeta plays a central role in activation of the p42/44 mitogen-activated protein kinase by endotoxin in alveolar macrophages. J. Immunol. 165: 4632-4639.
62. Häcker, H., H. Mischak, G. Häcker, S. Eser, N. Prenzel, A. Ullrich, and H. Wagner. 1999. Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells. EMBO J. 18: 6973-6982.
63. Lim, P. S., C. R. Sutton, and S. Rao. 2015. Protein kinase C in the immune system: from signalling to chromatin regulation. Immunology 146: 508-522.
64. Igumenova, T. I. 2015. Dynamics and membrane interactions of protein kinase C. Biochemistry 54: 4953-4968.
65. Do, Y., V. L. Hegde, P. S. Nagarkatti, and M. Nagarkatti. 2004. Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells. Cancer Res. 64: 6756-6765.
66. + T cell recognition of human melanoma cells following treatment with bryostatin-1. Cell. Immunol. 271: 392-400.
67. Brutkiewicz, R. R., C. A. Willard, K. K. Gillett-Heacock, M. R. Pawlak, J. C. Bailey, M. A. Khan, M. Nagala, W. Du, J. Gervay-Hague, and G. J. Renukaradhya. 2007. Protein kinase C delta is a critical regulator of CD1dmediated antigen presentation. Eur. J. Immunol. 37: 2390-2395.
68. Kawai, T., and S. Akira. 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34: 637-650.
69. Lemaitre, B., E. Nicolas, L. Michaut, J. M. Reichhart, and J. A. Hoffmann. 1996. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86: 973-983.
70. McGuire, V. A., and J. S. Arthur. 2015. Subverting toll-like receptor signaling by bacterial pathogens. Front. Immunol. 6: 607.
71. Brigl, M., L. Bry, S. C. Kent, J. E. Gumperz, and M. B. Brenner. 2003. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4: 1230-1237.
72. Holzapfel, K. L., A. J. Tyznik, M. Kronenberg, and K. A. Hogquist. 2014. Antigen-dependent versus-independent activation of invariant NKT cells during infection. J. Immunol. 192: 5490-5498.
73. Moreno, M., B. M. Mol, S. von Mensdorff-Pouilly, R. H. Verheijen, E. C. de Jong, B. M. von Blomberg, A. J. van den Eertwegh, R. J. Scheper, and H. J. Bontkes. 2009. Differential indirect activation of human invariant natural killer T cells by Toll-like receptor agonists. Immunotherapy 1: 557-570.
74. Selvanantham, T., N. K. Escalante, M. Cruz Tleugabulova, S. Fiévé, S. E. Girardin, D. J. Philpott, and T. Mallevaey. 2013. Nod1 and Nod2 enhance TLR-mediated invariant NKT cell activation during bacterial infection. J. Immunol. 191: 5646-5654.
75. Villanueva, A. I., S. M. Haeryfar, B. A. Mallard, R. R. Kulkarni, and S. Sharif. 2015. Functions of invariant NK T cells are modulated by TLR ligands and IFN-α. Innate Immun. 21: 275-288.
76. Vultaggio, A., F. Nencini, S. Pratesi, G. Petroni, S. Romagnani, and E. Maggi. 2012. Poly(I:C) promotes the production of IL-17A by murine CD1d-driven invariant NKT cells in airway inflammation. Allergy 67: 1223-1232.
77. + T cell response. Immunity 25: 655-664.
78. Assier, E., V. Marin-Esteban, A. Haziot, E. Maggi, D. Charron, and N. Mooney. 2007. TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation. J. Leukoc. Biol. 81: 221-228.
79. Siddiqui, S., A. Alatery, A. Kus, and S. Basta. 2011. TLR engagement prior to virus infection influences MHC-I antigen presentation in an epitope-dependent manner as a result of nitric oxide release. J. Leukoc. Biol. 89: 457-468.
80. Tobian, A. A., N. S. Potter, L. Ramachandra, R. K. Pai, M. Convery, W. H. Boom, and C. V. Harding. 2003. Alternate class I MHC antigen processing is inhibited by Toll-like receptor signaling pathogen-associated molecular patterns: Mycobacterium tuberculosis 19-kDa lipoprotein, CpG DNA, and lipopolysaccharide. J. Immunol. 171: 1413-1422.
81. + T cell responses. J. Immunol. 185: 1429-1441.
82. Santone, M., S. Aprea, T. Y. Wu, M. P. Cooke, M. L. Mbow, N. M. Valiante, J. S. Rush, S. Dougan, A. Avalos, H. Ploegh, et al. 2015. A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells. Hum. Vaccin. Immunother. 11: 2038-2050.
83. Kool, M., C. Geurtsvankessel, F. Muskens, F. B. Madeira, M. van Nimwegen, H. Kuipers, K. Thielemans, H. C. Hoogsteden, H. Hammad, and B. N. Lambrecht. 2011. Facilitated antigen uptake and timed exposure to TLR ligands dictate the antigen-presenting potential of plasmacytoid DCs. J. Leukoc. Biol. 90: 1177-1190.
84. Noss, E. H., R. K. Pai, T. J. Sellati, J. D. Radolf, J. Belisle, D. T. Golenbock, W. H. Boom, and C. V. Harding. 2001. Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J. Immunol. 167: 910-918.
85. Gehring, A. J., R. E. Rojas, D. H. Canaday, D. L. Lakey, C. V. Harding, and W. H. Boom. 2003. The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2. Infect. Immun. 71: 4487-4497.
86. Bakhru, P., N. Sirisaengtaksin, E. Soudani, S. Mukherjee, A. Khan, and C. Jagannath. 2014. BCG vaccine mediated reduction in the MHC-II expression of macrophages and dendritic cells is reversed by activation of Toll-like receptors 7 and 9. Cell. Immunol. 287: 53-61.
87. +) T cells. Immunity 36: 782-794.
88. + dendritic cells regulate the sensitivity of CD4 T-cell responses to bacterial flagellin. Mucosal Immunol. 7: 68-77.
89. Strong, B. S., and E. R. Unanue. 2011. Presentation of type B peptide-MHC complexes from hen egg white lysozyme by TLR ligands and type I IFNs independent of H2-DM regulation. J. Immunol. 187: 2193-2201.
90. O'Shea, J. J., and R. Plenge. 2012. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36: 542-550.
91. O'Shea, J. J., S. M. Holland, and L. M. Staudt. 2013. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 368: 161-170.
92. Christova, R., T. Jones, P. J. Wu, A. Bolzer, A. P. Costa-Pereira, D. Watling, I. M. Kerr, and D. Sheer. 2007. P-STAT1 mediates higher-order chromatin remodelling of the human MHC in response to IFNgamma. J. Cell Sci. 120: 3262-3270.
93. Miller, D. M., C. M. Cebulla, and D. D. Sedmak. 2002. Human cytomegalovirus inhibition of major histocompatibility complex transcription and interferon signal transduction. Curr. Top. Microbiol. Immunol. 269: 153-170.
94. Liu, W. H., J. J. Liu, J. Wu, L. L. Zhang, F. Liu, L. Yin, M. M. Zhang, and B. Yu. 2013. Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One 8: e55487.
95. Olszak, T., J. F. Neves, C. M. Dowds, K. Baker, J. Glickman, N. O. Davidson, C. S. Lin, C. Jobin, S. Brand, K. Sotlar, et al. 2014. Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature 509: 497-502.
96. Iyer, A. K., J. Liu, R. M. Gallo, M. H. Kaplan, and R. R. Brutkiewicz. 2015. STAT3 promotes CD1d-mediated lipid antigen presentation by regulating a critical gene in glycosphingolipid biosynthesis. Immunology 146: 444-455.
97. Wilson, R. P., M. L. Ives, G. Rao, A. Lau, K. Payne, M. Kobayashi, P. D. Arkwright, J. Peake, M. Wong, S. Adelstein, et al. 2015. STAT3 is a critical cell-intrinsic regulator of human unconventional T cell numbers and function. J. Exp. Med. 212: 855-864.
98. Ridley, A. J. 2006. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 16: 522-529.
99. Riento, K., and A. J. Ridley. 2003. Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 4: 446-456.
100. Bernard, O. 2007. Lim kinases, regulators of actin dynamics. Int. J. Biochem. Cell Biol. 39: 1071-1076.
101. Gallo, R. M., M. A. Khan, J. Shi, R. Kapur, L. Wei, J. C. Bailey, J. Liu, and R. R. Brutkiewicz. 2012. Regulation of the actin cytoskeleton by Rho kinase controls antigen presentation by CD1d. J. Immunol. 189: 1689-1698.
102. Torreno-Pina, J. A., C. Manzo, M. Salio, M. C. Aichinger, A. Oddone, M. Lakadamyali, D. Shepherd, G. S. Besra, V. Cerundolo, and M. F. Garcia-Parajo. 2016. The actin cytoskeleton modulates the activation of iNKT cells by segregating CD1d nanoclusters on antigen-presenting cells. Proc. Natl. Acad. Sci. USA 113: E772-E781.
103. Dhillon, A. S., S. Hagan, O. Rath, and W. Kolch. 2007. MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290.
104. Panka, D. J., M. B. Atkins, and J. W. Mier. 2006. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin. Cancer Res. 12: 2371s-2375s.
105. Roberts, P. J., and C. J. Der. 2007. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
106. Leicht, D. T., V. Balan, A. Kaplun, V. Singh-Gupta, L. Kaplun, M. Dobson, and G. Tzivion. 2007. Raf kinases: function, regulation and role in human cancer. Biochim. Biophys. Acta 1773: 1196-1212.
107. Mimura, K., K. Shiraishi, A. Mueller, S. Izawa, L. F. Kua, J. So, W. P. Yong, H. Fujii, B. Seliger, R. Kiessling, and K. Kono. 2013. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J. Immunol. 191: 6261-6272.
108. Hu-Lieskovan, S., S. Mok, B. Homet Moreno, J. Tsoi, L. Robert, L. Goedert, E. M. Pinheiro, R. C. Koya, T. G. Graeber, B. Comin-Anduix, and A. Ribas. 2015. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med. 7: 279ra41.
109. + T-cell recognition of melanoma. Cancer Immunol. Res. 3: 602-609.
110. Ostrand-Rosenberg, S., P. Sinha, O. Chornoguz, and C. Ecker. 2012. Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunol. Immunother. 61: 1319-1325.
111. Schett, G., J. Zwerina, and G. Firestein. 2008. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann. Rheum. Dis. 67: 909-916.
112. Medders, K. E., and M. Kaul. 2011. Mitogen-activated protein kinase p38 in HIV infection and associated brain injury. J. Neuroimmune Pharmacol. 6: 202-215.
113. Bode, J. G., C. Ehlting, and D. Häussinger. 2012. The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell. Signal. 24: 1185-1194.
114. Ansell, S. M., A. M. Lesokhin, I. Borrello, A. Halwani, E. C. Scott, M. Gutierrez, S. J. Schuster, M. M. Millenson, D. Cattry, G. J. Freeman, et al. 2015. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372: 311-319.
115. Tulunay, A., M. G. Dozmorov, F. Ture-Ozdemir, V. Yilmaz, E. Eksioglu-Demiralp, F. Alibaz-Oner, G. Ozen, J. D. Wren, G. Saruhan-Direskeneli, A. H. Sawalha, and H. Direskeneli. 2015. Activation of the JAK/STAT pathway in Behcet's disease. Genes Immun. 16: 170-175.
116. Nieminen, J. K., M. Niemi, T. Sipponen, H. M. Salo, P. Klemetti, M. Färkkilä, J. Vakkila, and O. Vaarala. 2013. Dendritic cells from Crohn's disease patients show aberrant STAT1 and STAT3 signaling. PLoS One 8: e70738.
117. Hedl, M., A. Lahiri, K. Ning, J. H. Cho, and C. Abraham. 2014. Pattern recognition receptor signaling in human dendritic cells is enhanced by ICOS ligand and modulated by the Crohn's disease ICOSLG risk allele. Immunity 40: 734-746.
118. Savva, A., and T. Roger. 2013. Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front. Immunol. 4: 387.
119. Mifsud, E. J., A. C. Tan, and D. C. Jackson. 2014. TLR agonists as modulators of the innate immune response and their potential as agents against infectious disease. Front. Immunol. 5: 79.
120. Cervantes, J. L., K. L. Hawley, S. J. Benjamin, B. Weinerman, S. M. Luu, and J. C. Salazar. 2014. Phagosomal TLR signaling upon Borrelia burgdorferi infection. Front. Cell. Infect. Microbiol. 4: 55.
121. Skevaki, C., M. Pararas, K. Kostelidou, A. Tsakris, and J. G. Routsias. 2015. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases. Clin. Exp. Immunol. 180: 165-177.
122. Song, B., Y. Zhang, L. Chen, T. Zhou, W. Huang, X. Zhou, and L. Shao. 2016. The role of Toll-like receptors in periodontitis. Oral Dis.
123. Marques, C. P., Y. Maor, M. S. de Andrade, V. P. Rodrigues, and B. B. Benatti. 2016. Possible evidence of systemic lupus erythematosus and periodontal disease association mediated by Toll-like receptors 2 and 4. Clin. Exp. Immunol. 183: 187-192.
124. Trejo-de la O, A., P. Hernández-Sancén, and C. Maldonado-Bernal. 2014. Relevance of single-nucleotide polymorphisms in human TLR genes to infectious and inflammatory diseases and cancer. Genes Immun. 15: 199-209.
125. Mohammad Hosseini, A., J. Majidi, B. Baradaran, and M. Yousefi. 2015. Toll-like receptors in the pathogenesis of autoimmune diseases. Adv. Pharm. Bull. 5(Suppl. 1): 605-614.
126. Medvedev, A. E. 2013. Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer. J. Interferon Cytokine Res. 33: 467-484.
127. Ve, T., N. J. Gay, A. Mansell, B. Kobe, and S. Kellie. 2012. Adaptors in toll-like receptor signaling and their potential as therapeutic targets. Curr. Drug Targets 13: 1360-1374.
128. Page, D. B., M. A. Postow, M. K. Callahan, J. P. Allison, and J. D. Wolchok. 2014. Immune modulation in cancer with antibodies. Annu. Rev. Med. 65: 185-202.
129. Sharma, P., and J. P. Allison. 2015. The future of immune checkpoint therapy. Science 348: 56-61.